---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-060352"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T16:47:49.844433+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology reports Q3 2023 net loss $23.0M; cuts headcount 40% to extend cash runway into early 2026

## Summary
- Net loss of $23.0M ($0.56 per share) for Q3 2023, vs $27.7M ($0.85 per share) in Q3 2022.
- Cash, restricted cash, and short-term investments total $134.4M as of Sept 30, 2023.
- Announces 40% headcount reduction and pausing early-stage research to extend cash runway into early 2026.
- PYX-201 Phase 1 fifth dose cohort at 3.6 mg/kg; preliminary data expected 1H 2024. PYX-106 refocused on NSCLC; data expected 2H 2024.

## SEC filing metadata
- accession: 0000950170-23-060352
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017023060352/0000950170-23-060352-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017023060352/pyxs-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-060352
- JSON: https://secwatch.observer/filing/0000950170-23-060352.json
- Plain text: https://secwatch.observer/filing/0000950170-23-060352.txt

## Key facts
- Earnings Releases
  Pyxis Oncology, Inc. reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: On November 7, 2023, Pyxis Oncology, Inc., or the Company, issued a press release announcing its financial results for the quarter ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000095017023060352/0000950170-23-060352-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.